Bayer Faces September Glyphosate Hearing as Japan Approves Hyrnuo
Bayer’s shares rise as Japan’s health ministry approves Hyrnuo (Sevabertinib) for targeted lung cancer treatment, the first for that indication in Japan. At the same time, the company tightened its net debt target to €29–30 billion by 2026 year-end. A Missouri court also pushed the multibillion-euro glyphosate settlement hearing to September 14.